The IXIARO vaccine. Focused protection for travelers and military personnel

IXIARO by Valneva lands in the travel clinic fridge as a compact white box with a blue stripe, the kind you notice when the nurse opens the cold cabinet and the air smells sharply of disinfectant. One batch number, one destination: protection against Japanese encephalitis before the next long-haul flight.

Who IXIARO is made for

Valneva developed IXIARO as an inactivated Japanese encephalitis vaccine for adults and children from two months of age who travel to or live in endemic areas such as parts of Asia and the Western Pacific. Thomas Lingelbach, Valneva’s long-time CEO, has repeatedly framed the company’s travel vaccines as “targeted solutions” for well-defined risk groups. In practice, that means business travelers to Tokyo, backpackers through rural Vietnam, and soldiers deploying to tropical bases.

Unlike childhood vaccines given routinely, IXIARO is usually offered in specialized travel clinics or hospital outpatient departments. A complete primary series consists of two 0.5 ml doses given intramuscularly, typically on Day 0 and Day 28. The injection itself feels like any other modern vaccine: a brief sting, then a dull ache in the upper arm that reminds you for a few hours that your immune system is working.

How the vaccine works

IXIARO contains inactivated Japanese encephalitis virus derived from the SA14-14-2 strain, produced on cell culture and adsorbed to aluminum hydroxide as an adjuvant. Because the virus is killed, it cannot cause the disease, but it still presents the key antigens that train the immune system to recognize and neutralize the real pathogen. Valneva’s clinical data show that more than 95% of adults develop protective neutralizing antibody titers after the two-dose schedule. For healthcare staff like travel physician Dr. Claudia Metz in Berlin, that seroconversion rate is the central number when deciding whether to recommend the shot.

The vaccine is supplied as a ready-to-use suspension in pre-filled syringes and must be stored between 2 °C and 8 °C. When the nurse gently rolls the syringe between her fingers to mix the milky liquid before injection, you see fine air bubbles rise and burst against the plastic wall. That routine moment is backed by a long manufacturing chain: cell culture, inactivation, purification, formulation, and quality release in Valneva’s facilities.

Dosing schedules and updates

Regulators such as the European Medicines Agency have approved IXIARO for use in adults and children from 2 months of age, with age-dependent dosing schedules. Infants from 2 months to under 3 years receive 0.25 ml per dose, while older children and adults receive the full 0.5 ml volume. Public health agencies like the US CDC recommend the vaccine for people spending at least one month in endemic areas or engaging in activities that increase risk, such as working in rice fields or staying in rural villages.

Booster guidance has evolved as more immunogenicity data accumulated. Current labeling states that a booster dose can be given 12 to 24 months after completion of the primary series if continued or repeated exposure is expected. Military medical services have integrated that schedule into deployment protocols, so soldiers heading back to the same region several years later can get a quick top-up. For travelers, physicians like Dr. Metz usually assess individual risk: a short city trip may not justify a booster, a long stay in rural zones often does.

Position in Valneva’s portfolio

IXIARO is one of Valneva’s commercial vaccines, alongside the cholera and traveler’s diarrhea product Dukoral and the chikungunya vaccine IXCHIQ. Valneva describes itself as a specialty vaccine company, focused on diseases with significant unmet medical need or targeted risk populations rather than mass-market routine immunizations. In the company’s latest annual report, travel and endemic vaccines form a distinct revenue segment that analysts watch closely as a stabilizing cash flow next to newer launches.

Within that segment, IXIARO stands out because Japanese encephalitis is a serious, potentially fatal infection with limited treatment options. Case numbers are relatively low compared to flu or measles, but the consequences can be devastating: neurologic sequelae, long hospital stays, and considerable costs. That imbalance between incidence and severity is exactly where Valneva aims to sit. For institutional buyers such as defense ministries, the value proposition is straightforward: a scheduled vaccine program is easier to budget than evacuation flights and intensive care beds.

Manufacturing, supply and regulators

Valneva manufactures IXIARO in its specialized vaccine facilities in Europe, with quality oversight aligned to EMA and other major regulators. The product’s European marketing authorization originally went under the name IXIARO, while in some markets like Australia a related formulation is branded JESPECT for local distribution. That multiple-brand approach is common in the vaccine industry when partners handle regional promotion and supply chains.

Regulatory documents available through the EMA and national drug agencies detail IXIARO’s composition, stability, and contraindications. The vaccine should not be given to individuals with known hypersensitivity to any component, including excipients such as potassium phosphate and sodium chloride. In the travel clinic, this translates into routine pre-vaccination questions about previous allergic reactions. If a patient hesitates and says, “My arm swelled badly after a flu shot,” physicians like Dr. Metz weigh that history against the planned exposure and may choose alternative measures such as mosquito avoidance only.

Safety profile and real-world use

Across clinical trials and post-marketing surveillance, IXIARO has shown a safety profile broadly comparable to other inactivated vaccines. Common side effects include pain and tenderness at the injection site, headache, and mild fatigue, typically resolving within a couple of days. Serious adverse events are rare and monitored through pharmacovigilance systems in Europe, North America, and Asia. Travel medicine centers that administer the vaccine typically maintain their own incident logs in addition to national reporting obligations, adding an extra layer of real-world oversight.

Over the past decade, the vaccine has become a standard item on pre-travel checklists for long-term stays in endemic regions. Travel health guidelines from multiple countries mention it by brand name or as the preferred modern Japanese encephalitis vaccine. In practice, uptake depends on risk communication: if the consultation focuses only on common issues such as traveler’s diarrhea and sunburn, people may skip the shot. When physicians describe Japanese encephalitis as a brain infection transmitted by mosquitoes, with a risk concentrated in rural areas and rice paddies, many travelers accept the additional cost and injection.

Business context and stock

For Valneva, IXIARO provides recurring revenue tied to travel flows, military deployments, and corporate assignments abroad. That demand pattern can be cyclical – it dropped during the COVID-19 pandemic when international travel collapsed and then recovered as borders reopened. Analysts following Valneva SE highlight the travel vaccine franchise, including IXIARO, as an important component that balances the risk of newer pipeline assets. On Xetra, Valneva SE stock trades in euro, and the performance of established products like IXIARO feeds into investor expectations without changing the company’s profile as a high-risk biotech play.